Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Cell Chem Biol. 2019 Jun 20;26(6):804-817.e12. doi: 10.1016/j.chembiol.2019.02.015. Epub 2019 Mar 28.
Cyclin-dependent kinase 14 (CDK14) and other TAIRE family kinases (CDKs 15-18) are proteins that lack functional annotation but are frequent off-targets of clinical kinase inhibitors. In this study we develop and characterize FMF-04-159-2, a tool compound that specifically targets CDK14 covalently and possesses a TAIRE kinase-biased selectivity profile. This tool compound and its reversible analog were used to characterize the cellular consequences of covalent CDK14 inhibition, including an unbiased investigation using phospho-proteomics. To reduce confounding off-target activity, washout conditions were used to deconvolute CDK14-specific effects. This investigation suggested that CDK14 plays a supporting role in cell-cycle regulation, particularly mitotic progression, and identified putative CDK14 substrates. Together, these results represent an important step forward in understanding the cellular consequences of inhibiting CDK14 kinase activity.
周期蛋白依赖性激酶 14(CDK14)和其他 TAIRE 家族激酶(CDKs15-18)是缺乏功能注释但却是临床激酶抑制剂频繁的非靶点的蛋白质。在这项研究中,我们开发并表征了 FMF-04-159-2,这是一种专门针对 CDK14 共价结合的工具化合物,具有 TAIRE 激酶偏向的选择性特征。该工具化合物及其可逆类似物被用于表征共价 CDK14 抑制的细胞后果,包括使用磷酸化蛋白质组学进行无偏见的研究。为了减少混杂的非靶点活性,使用洗脱条件来分解 CDK14 特异性作用。这项研究表明,CDK14 在细胞周期调控中发挥支持作用,特别是在有丝分裂进展中,并确定了潜在的 CDK14 底物。总之,这些结果代表着在理解抑制 CDK14 激酶活性的细胞后果方面向前迈出了重要的一步。